Sharemaestro Newsreel

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

Daré Bioscience reported its Q2 2026 financial results, highlighting significant progress in its multi-product women's health strategy. The company launched Flora Sync LF5 and is preparing for national dispensing of DARE to PLAY Sildenafil Cream, expecting initial revenue in Q3 2026. Daré also provided …

Dare Bioscience, Inc. 2026: Revenue $187.55K, EPS ($0.2) — 10-Q Summary

Dare Bioscience, Inc. reported its 2026 quarterly results, with revenue of $187.55K and a net loss of ($2.98M), which is an improvement from the prior year's loss. The company saw revenue growth due to Gates Foundation agreements and the launch of new products and …

MacroGenics GAAP EPS of -$1.10 misses by $1.02, revenue of $32.83M misses by $26.31M

* MacroGenics press release [https://seekingalpha.com/pr/20619132-macrogenics-reports-second-quarter-2026-financial-results-streamlined-operating-model-and] (MGNX [https://seekingalpha.com/symbol/MGNX]): Q2 GAAP EPS of -$1.10 misses by $1.02. * Revenue of $32.83M (+377.9% Y/Y) misses by $26.31M. MORE ON MACROGENICS * MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important [https://seekingalpha.com/article/4925873-macrogenics-whipsaws-on-clinical-data-but-the-big-picture-is-still-important] * MacroGenics: 'Hold' …

4D Molecular Therapeutics (FDMT) posts $141.7M first-half 2026 net loss

Mark Mossler (CCCC) files to sell 15,000 shares after recent stock sales

Mark Mossler has filed a Form 144 to sell 15,000 shares of C4 Therapeutics, Inc. (CCCC) common stock, acquired through a stock option exercise. The aggregate market value of this planned sale is $61,072.50, and the transaction is expected to occur on or after …

Eikon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

CAMP4 Therapeutics (CAMP) widens Q2 2026 loss, boosts cash runway to 2028

CAMP4 Therapeutics reported a wider net loss of $33.5 million in Q2 2026, primarily due to a non-cash loss from a derivative liability. Despite this, the company's research and collaboration revenue increased, and it successfully extended its cash runway through the end of 2028 …

CAMP4 Therapeutics (Nasdaq: CAMP) widens loss as derivative liability surges

CAMP4 Therapeutics reported a widened net loss of $51.86 million for the six months ended June 30, 2026, primarily due to a $27.12 million non-cash charge from the remeasurement of a derivative tranche liability. Despite the loss, the company extended its cash runway through …

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Therapeutics announced its Q2 2026 financial results and corporate highlights, including securing regulatory clearance in Australia and Argentina for its Phase 1/2 clinical trial of CMP-002 for SYNGAP-1 related disorder, with trial initiation expected in Q4 2026. The company also raised an additional …

Eikon Therapeutics, Inc. 2Q 2026: Net income $(88.4)M, EPS $(1.63) — 10-Q Summary

Eikon Therapeutics, Inc. reported a net loss of $(88.4)M, or $(1.63) per share, for the second quarter of 2026, showing an improvement compared to the previous year. The company maintains $531.2M in cash and equivalents, sufficient for near-term operations for at least a year. …

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Edesa Biotech (Nasdaq: EDSA) reported its fiscal third-quarter 2026 results, showing a net loss of $5.4 million due to increased operating expenses. The company announced it has completed preparations for its Phase 2 EB06 vitiligo trial and begun activating initial investigational sites, with patient …

FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise

A stockholder of 4D Molecular Therapeutics, Inc. (FDMT) has filed to sell 1,635 common shares on NASDAQ, to be issued through the exercise of stock options for cash on August 13, 2026. This filing also discloses previous Rule 10b5-1 plan sales by Scott Bizily …

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular Therapeutics (4DMT) reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for wet AMD and DME, including completed enrollment for two Phase 3 trials for 4D-150 and strong two-year data from its PRISM Phase 2b study. The company …

Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal

Aspire Biopharma (NASDAQ: ASBP) slashes H1 2026 loss and rebuilds equity

Aspire Biopharma (NASDAQ: ASBP) reported significantly reduced net losses in the first half of 2026, dropping to $4.49 million from $17.92 million a year prior, largely due to lower stock-based compensation and financing costs. The company also substantially improved its balance sheet, moving from …

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech reported a 14% increase in total net revenue to $18.7 million for Q2 2026 compared to Q2 2025, driven by commercial portfolio growth and advancements in partnered programs. Key highlights include Crystalys Therapeutics' $130 million Series B financing for dotinurad, expansion of …

Crystalys Raises $130M to Advance Its Once-Daily Gout Drug

Fortress Biotech (Nasdaq: FBIO) reported a 14% increase in Q2 2026 net revenue to $18.7 million, primarily driven by dermatology product sales. The company's cash and cash equivalents significantly rose to $196.6 million, aided by the monetization of a ZYCUBO® priority review voucher. Key …

PDS Biotechnology (PDSB) cuts R&D spend but warns on going concern, cash at $5.6M

PDS Biotechnology reported a net loss of $17.1 million for the six months ended June 30, 2026, with cash and cash equivalents significantly reduced to $5.6 million from $26.7 million at year-end 2025. The company's management disclosed substantial doubt about its ability to continue …

IMMUCELL CORP /DE/ Q2 2026: Revenue $7.19M, EPS $0.2— 10-Q Summary

IMMUCELL CORP /DE/ (ICCC) reported strong second-quarter 2026 results, with revenue reaching $7.19M and diluted EPS of $0.20, significantly up from the previous year. This growth was primarily driven by increased volumes and pricing for its First Defense product, which accounted for over 99% …

ImmuCell Plans About $4.5M Expansion for Calf Health Products

ImmuCell (NASDAQ: ICCC) reported strong Q2 2026 financial results with product sales up 11.5% to $7.2 million and net income rising to $1.8 million, aided by a $2 million legal settlement. The company announced a two-phase, approximately $8.0 million expansion of its First Defense® …

ImmuCell Corporation (ICCC) doubles profit on higher First Defense sales

ImmuCell Corporation reported robust financial results for the first half of 2026, with net income doubling to $3.8 million due to increased First Defense sales and a significant $2.0 million settlement. The company's product sales grew by 20.9% to $17.5 million, largely driven by …

Rani Therapeutics' Oral RT-114 Tops 150% Bioavailability

Rani Therapeutics reported its Q2 2026 financial results, including a net loss of $8.4 million and contract revenue of $1.7 million, with cash reserves of $53.4 million expected to fund operations through 2027. The company announced positive initial Phase 1a data for its oral …

CG Oncology (CGON): Wellington group discloses 5.3M-share, 6.04% ownership position

A group of affiliated Wellington entities has disclosed a beneficial ownership of 5,324,751 shares of CG Oncology (CGON) common stock, representing 6.04% of the class. This disclosure, filed via a SCHEDULE 13G/A, indicates shared voting power over 4,637,354 shares and shared dispositive power over …

Wellington group discloses over 5% Cytokinetics (CYTK) holding for clients

Wellington Management Group LLP and related entities have disclosed a 5.12% beneficial ownership stake in Cytokinetics, Incorporated (CYTK) for their clients, as detailed in an Amendment No. 2 to a Schedule 13G filing. This holding, totaling 7,116,724 shares, is managed by various Wellington investment …

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. announced inducement grants to Ms. Beth Rada, the new SVP of Government Affairs and Public Policy. These awards, consisting of stock options and restricted stock units, were granted under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule …

Ocular Therapeutix’s New Policy Leader Gets an 85,000-Share Option

Ocular Therapeutix (NASDAQ: OCUL) has granted its new SVP, Government Affairs and Public Policy, Beth Rada, inducement equity awards under its 2019 Inducement Stock Incentive Plan. These awards, effective August 10, 2026, include a non-statutory option to purchase up to 85,000 shares at $9.24 …

Silo Pharma (SILO) trims cash burn, mitigates going-concern risk in Q2 2026

Silo Pharma, Inc. (SILO) reported a net loss of $2.48 million for the six months ended June 30, 2026, driven by operational costs and R&D investments, despite generating $18,026 in license fee revenue. The company maintains a strong liquidity position with $3.28 million in …

Edgewise Therapeutics, Inc. SEC Filing (Aug 13, 2026)

Edgewise Therapeutics, Inc. (EWTX) filed a Form 144 with the SEC on August 13, 2026, indicating a proposed sale of securities. The filing details the sale of 2,919 shares of common stock with an aggregate market value of $127,151.64 by an individual who acquired …

OMEROS CORP SEC Filing (Aug 13, 2026)

This article details an SEC Form 144 filing by Omeros Corp (OMER) on August 13, 2026. The filing indicates a proposed sale of 5,000 shares of common stock, valued at $68,550.00, resulting from the exercise of stock options. The shares are to be sold …

Affinity Asset Advisors discloses 6.4% NextCure (NXTC) stake via stock and warrants

Affinity Asset Advisors, along with its managing member Michael Cho, has disclosed a 6.4% beneficial ownership stake in NextCure, Inc. (NXTC) as of June 30, 2026. This stake includes 274,073 shares, with 232,113 shares issuable upon the exercise of warrants, which are subject to …

Gossamer Bio: Q2 Earnings Snapshot

Sarepta Therapeutics (SRPT) Tightened 2026 Revenue Guidance, Is The Stock Still A Bargain?

Sarepta Therapeutics recently tightened its 2026 revenue guidance to $1.2 billion to $1.3 billion and announced second-quarter results and pipeline updates. Despite a 15.38% share price jump over the last 7 days, the stock is down 13.75% year-to-date and 83.87% over three years. Analysts …

Biomea Fusion doses first patient in icovamenib-semaglutide study

Biomea Fusion, Inc. (NASDAQ:BMEA) has dosed the first patient in a new arm of its OPAL platform study, evaluating the combination of icovamenib and low-dose semaglutide. This randomized double-blind study aims to assess whether adding icovamenib can enhance weight loss and improve physical function, …

Renaissance Technologies (BOLT) reports 5.13% ownership stake in Bolt Biotherapeutics

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a 5.13% ownership stake in Bolt Biotherapeutics, Inc., amounting to 98,625 shares. Both entities, based in Delaware, hold sole voting and dispositive power over these shares, with certain managed funds having rights to dividends …

Cibus (CBUS) cuts costs but warns on going concern amid Q2 2026 loss

Cibus (CBUS) reported a Q2 2026 net loss of $22.1 million and a year-to-date net loss of $43.4 million, along with a warning about its ability to continue as a going concern due to recurring losses and limited cash. Despite modest revenue growth and …

ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D